Jensen Investment Management Inc. Lowers Stock Holdings in Encompass Health Co. (NYSE:EHC)

Jensen Investment Management Inc. decreased its position in shares of Encompass Health Co. (NYSE:EHC) by 11.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 81,730 shares of the company’s stock after selling 10,480 shares during the quarter. Jensen Investment Management Inc. owned approximately 0.08% of Encompass Health worth $7,548,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. State Street Corp lifted its stake in shares of Encompass Health by 0.7% during the 3rd quarter. State Street Corp now owns 3,025,769 shares of the company’s stock valued at $292,410,000 after buying an additional 21,329 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Encompass Health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock valued at $161,781,000 after buying an additional 20,547 shares in the last quarter. Copeland Capital Management LLC lifted its stake in shares of Encompass Health by 0.7% during the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock valued at $119,418,000 after buying an additional 8,548 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Encompass Health by 2,458.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock valued at $83,990,000 after buying an additional 835,135 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Encompass Health in the 4th quarter worth $77,944,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

Shares of NYSE:EHC opened at $96.11 on Monday. The company has a market capitalization of $9.68 billion, a price-to-earnings ratio of 21.55, a PEG ratio of 2.31 and a beta of 0.92. Encompass Health Co. has a 12 month low of $74.45 and a 12 month high of $104.55. The firm’s 50-day moving average is $97.35 and its 200 day moving average is $96.97. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Research analysts predict that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st will be paid a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.71%. Encompass Health’s dividend payout ratio is currently 15.25%.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. KeyCorp boosted their price target on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, February 15th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. Barclays boosted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a research report on Tuesday, February 11th. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $107.67.

Insiders Place Their Bets

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.10% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.